<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The cardiopulmonary exercise test (CPX) is an affordable tool for risk prediction in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to determine the role of CPX parameters in predicting the risk of incidence of sustained <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> (SVA) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Sixty-one consecutive patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> enrolled in the Daunia <z:hpo ids='HP_0001635'>Heart Failure</z:hpo> Registry underwent CPX and were followed for 327 ± 247 days </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical follow-up was performed every month and anticipated in case of re-hospitalisation for <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Incidence of SVA was evaluated by direct clinical examination (ECG, ambulatory ECG) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Patients with episodes of SVA (N 14) showed lower values of pVO2 and PetCO2, and higher values of VE/VCO2, VE/VCO2 slope, and VE% </plain></SENT>
<SENT sid="6" pm="."><plain>After correction for age, gender, <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischaemic heart disease</z:e> and left ventricular ejection fraction, peak <z:chebi fb="1" ids="30047">VO2</z:chebi> (hazard ratio (HR) 0.68, 95 % confidence interval (CI) 0.51-0.91, p &lt; 0.05), VE% (HR 1.38, 95 % CI 1.04-1.84, p &lt; 0.05), VE/VCO2 (HR 1.38, 95 % CI 1.04-1.82, p &lt; 0.05), VE/VCO2 slope (HR 1.77, 95 % CI 1.31-2.39, p &lt; 0.01), PetCO2 (HR 0.66, 95 % CI 0.50-0.88, p &lt; 0.01) were found as predictors of SVA </plain></SENT>
<SENT sid="7" pm="."><plain>At Kaplan-Meier analysis, lower event-free rates were found in subjects with peak <z:chebi fb="1" ids="30047">VO2</z:chebi> values below median (log rank p &lt; 0.05), values of VE/VCO2 above mean (p &lt; 0.05), higher VE/VCO2 slope tertiles (p &lt;0.05), and values of PetCO2 below median (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: CPX provides prognostic independent information for risk of SVA in subjects with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
</text></document>